Evidence map›Paper›PMID 35678462›Full record

ReviewAmerican journal of medical genetics. Part A2022

Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis.

Vanessa L Merker, Bronwyn Slobogean, Justin T Jordan, Shannon Langmead, Mark Meterko, Martin P Charns, A Rani Elwy, Jaishri O Blakeley, Scott R Plotkin

Open access · greenAbstract readReview
In one paragraph

Review in American journal of medical genetics. Part A, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Frontiers in medicine · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Vanessa L MerkerDepartment of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4542-5227
Bronwyn SlobogeanDepartment of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.
Justin T JordanDepartment of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-6198-817X
Shannon LangmeadDepartment of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.
Mark MeterkoAnalytics and Performance Integration, Office of Quality and Patient Safety, Veterans Health Administration, Bedford, Massachusetts, USA.
Martin P CharnsDepartment of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, USA.
A Rani ElwyCenter for Healthcare Organization and Implementation Research (CHOIR), VA Bedford Healthcare System, Bedford, Massachusetts, USA.
Jaishri O BlakeleyDepartment of Neurology and Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0002-1049-0993
Scott R PlotkinDepartment of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Johns Hopkins University · USMassachusetts General Hospital · USBoston University · USBrown University · US

Funding

Program in Cancer Research Outcomes Training (PCORT)R25CA092203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI GAZELLE, G SCOTT · 2002 to 2016
$8.2M
NCI NIH HHS R25 CA092203
6 · The paper itself

Abstract

Diagnosis of rare, genetic diseases is challenging, but conceptual frameworks of the diagnostic process can guide quality improvement initiatives. Using the National Academy of Medicine diagnostic framework, we assessed the extent of, and reasons for diagnostic delays and diagnostic errors in schwannomatosis, a neurogenetic syndrome characterized by nerve sheath tumors and chronic pain. We reviewed the medical records of 97 people with confirmed or probable schwannomatosis seen in two US tertiary care clinics. Time-to-event analysis revealed a median time from first symptom to diagnosis of 16.7 years (95% CI, 7.5-26.0 years) and median time from first medical consultation to diagnosis of 9.8 years (95% CI, 3.5-16.2 years). Factors associated with longer times to diagnosis included initial signs/symptoms that were intermittent, non-specific, or occurred at younger ages (p < 0.05). Thirty-six percent of patients were misdiagnosed; misdiagnoses were of underlying genetic condition (18.6%), pain etiology (16.5%), and nerve sheath tumor presence/pathology (11.3%) (non-mutually exclusive categories). One-fifth (19.6%) of patients had a clear missed opportunity for genetics workup that could have led to an earlier schwannomatosis diagnosis. These results suggest that interventions in clinician education, genetic testing availability, expert review of pathology findings, and automatic triggers for genetics referrals may improve diagnosis of schwannomatosis.

Indexed as

NeurilemmomaNeurofibromatosesNeurofibromatosis 2Skin NeoplasmsHumansRare Diseasesdelayed diagnosisdiagnostic errorsmissed diagnosisrare diseaseschwannomatosis

Identifiers

PMID35678462
PMCPMC9378587
OpenAlexW4281968172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.